|
Sponsored by 
|
|
|
|
|
|
|
By Sharon Begley
APStock
The more mutations tumor cells have, the likelier a patient is to go into remission, and possibly be cured, by checkpoint inhibitors, study finds.
Read More
|
|
By Associated Press
Gerry Broome/AP
Lower smoking rates are translating into fewer deaths. Advances in early detection and treatment also are having a positive impact, experts say.
Read More
|
|
By Casey Ross
Rick Berke/STAT
After a string of costly failures in health care, CEO Ginni Rometty said IBM still believes in the potential of Watson to shake up the medical industry.
Read More
|
|
Sponsor content by Foundation Medicine
First FDA-approved comprehensive genomic profiling test provides options for advanced cancer patients
With the rapid pace of change in the understanding and management of personalized cancer treatment, comprehensive genomic profiling using an FDA-approved test like FoundationOne®CDx, is becoming increasingly important to identify relevant treatment options for advanced cancer patients. FoundationOne CDx is designed to provide physicians with clinically actionable information, both to consider appropriate therapies for patients and understand results with evidence of resistance, based on the individual genomic profile of a patient’s cancer.
Download your free clinical summary report.
|
|
By Matthew Herper
Mel Evans/AP
In the third quarter of 2018, sales of the drug reached $1.9 billion — 18 percent of Merck’s revenue. But the company says its portfolio remains diverse.
Read More
|
|
By Ed Silverman
DOMINICK REUTER/AFP/Getty Images
The convoluted case has spurred debate about orphan drug status and the ability of local hospitals to make their own lower-cost alternatives.
Read More
|
|
